AbbVie Acquires Apogee Therapeutics for $10.9 Billion
AbbVie will acquire Apogee Therapeutics, a clinical-stage biotech focused on inflammatory and immunological diseases, for $10.9 billion.
AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion, adding a clinical-stage pipeline of candidates for inflammatory and immunological diseases to its portfolio.
The deal involves AbbVie and Apogee Therapeutics, a biotech developing treatments for inflammatory and immunological conditions. The acquisition price is $10.9 billion, according to the announcement.
Continue reading
3 more paragraphs for subscribers.
Free readers get a daily preview and the weekly long-form. Premium unlocks every brief in full, AM & PM editions, alerts, and the archive.